Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Begonya Comin-Anduix"'
Autor:
Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Justin Saco, Helena Escuin-Ordinas, Gabriel Abril Rodriguez, Jesse M. Zaretsky, Lu Sun, Willy Hugo, Xiaoyan Wang, Giulia Parisi, Cristina Puig Saus, Davis Y. Torrejon, Thomas G. Graeber, Begonya Comin-Anduix, Siwen Hu-Lieskovan, Robert Damoiseaux, Roger S. Lo, Antoni Ribas
Publikováno v:
Cell Reports, Vol 19, Iss 6, Pp 1189-1201 (2017)
PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting checkpoint that can be induced in tumors by interferon exposure, leading to immune evasion. This process is important for immunotherapy based on PD-1 blockade. We examined the specific molecu
Externí odkaz:
https://doaj.org/article/e5b58d91cebc41a38766402ee83a9fa5
Autor:
Jing Zhou, Michael T Bethune, Natalia Malkova, Alexander M Sutherland, Begonya Comin-Anduix, Yapeng Su, David Baltimore, Antoni Ribas, James R Heath
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0191634 (2018)
For adoptive cell transfer (ACT) immunotherapy of tumor-reactive T cells, an effective therapeutic outcome depends upon cell dose, cell expansion in vivo through a minimally differentiated phenotype, long term persistence, and strong cytolytic effect
Externí odkaz:
https://doaj.org/article/4b46a5650dcb4af4a881a6f5f8c71eb3
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Autor:
Mohammad Atefi, Erika von Euw, Narsis Attar, Charles Ng, Connie Chu, Deliang Guo, Ramin Nazarian, Bartosz Chmielowski, John A Glaspy, Begonya Comin-Anduix, Paul S Mischel, Roger S Lo, Antoni Ribas
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e28973 (2011)
The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progres
Externí odkaz:
https://doaj.org/article/f5dd53cf6f154f0b8e16f8e436c784c9
Autor:
James F Curtin, Naiyou Liu, Marianela Candolfi, Weidong Xiong, Hikmat Assi, Kader Yagiz, Matthew R Edwards, Kathrin S Michelsen, Kurt M Kroeger, Chunyan Liu, A K M Ghulam Muhammad, Mary C Clark, Moshe Arditi, Begonya Comin-Anduix, Antoni Ribas, Pedro R Lowenstein, Maria G Castro
Publikováno v:
PLoS Medicine, Vol 6, Iss 1, p e10 (2009)
BackgroundGlioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune response in brain tumor patients have met with limited success, whi
Externí odkaz:
https://doaj.org/article/0adb0547db44421eb3369a03d288ff9a
Autor:
James R. Heath, Antoni Ribas, Begonya Comin-Anduix, James S. Economou, Bartosz Chmielowski, David Baltimore, Owen N. Witte, Alistair J. Cochran, Earl Avramis, Charles Ng, Zhongqi Wu, Richard C. Koya, Thinle Chodon, Ann F. Cheung, Chao Ma
PDF file - 1292K, Study scheme, assay validation, functional changes of patients F5-2 and F5-8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c88c6ea6e08bff6b02ca1f29de0080d
https://doi.org/10.1158/2159-8290.22529706
https://doi.org/10.1158/2159-8290.22529706
Autor:
James R. Heath, Antoni Ribas, Begonya Comin-Anduix, James S. Economou, Bartosz Chmielowski, David Baltimore, Owen N. Witte, Alistair J. Cochran, Earl Avramis, Charles Ng, Zhongqi Wu, Richard C. Koya, Thinle Chodon, Ann F. Cheung, Chao Ma
PDF file - 131K, Protein and cell specificity studied, comparison of polyfunctional T cells and other cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f844709dc1c07426793e01027d818f
https://doi.org/10.1158/2159-8290.22529703
https://doi.org/10.1158/2159-8290.22529703
Autor:
Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Thinle Chodon, Bjoern Titz, Michael Cerniglia, David Foulad, Lidia Robert, Deborah J.L. Wong, Amanda Lassen, Earl Avramis, Mohammad Atefi
Purpose: PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether PD-L1 expression is controlled by melanoma driver mutations and modified by oncog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dfbc2f2b0a21e3861c54fc6c8ba22cc
https://doi.org/10.1158/1078-0432.c.6521649
https://doi.org/10.1158/1078-0432.c.6521649
Autor:
Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Thinle Chodon, Bjoern Titz, Michael Cerniglia, David Foulad, Lidia Robert, Deborah J.L. Wong, Amanda Lassen, Earl Avramis, Mohammad Atefi
PDF file - 247KB, MAPK pathway is almost inactive in resting PBMCs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f944be37873d04b3ffda49b9be5fec
https://doi.org/10.1158/1078-0432.22449408
https://doi.org/10.1158/1078-0432.22449408
Autor:
Adrian Bot, Mihail Obrocea, Zhiyong Qiu, David C. Diamond, Sabrina Miles, Darlene Rosario, Elizabeth Seja, Steve Raman, Nagesh Ragavendra, Michael Douek, David Lu, Begonya Comin-Anduix, Bartosz Chmielowski, Jeffrey S. Weber, Antoni Ribas
Supplementary Figures S1-S5; Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06d5b5c9771a271569c5bf2f50ce2eca
https://doi.org/10.1158/1078-0432.22441191
https://doi.org/10.1158/1078-0432.22441191
Autor:
Antoni Ribas, Beata Berent-Maoz, Paula J. Kaplan-Lefko, Paula Cabrera, Xiaoyan Wang, Donald B. Kohn, Begonya Comin-Anduix, David Baltimore, Owen N. Witte, Lili Yang, Alexander Nguyen, Celia Adelson, Eric H. Gschweng, Kenneth Cornetta, Daniela Bischof, Beatriz Campo-Fernandez, Roger P. Hollis, Gay M. Crooks, Amelie Montel-Hagen, Christopher S. Seet, Brad Bolon, Jeffrey L. Goodwin, Justin D. Saco, Mignonette H. Macabali, Jia Pang, Marie Desiles S. Komenan, Agustin Vega-Crespo, Nhat A. Truong, Gardenia C. Cheung-Lau, James McCabe, Ameya S. Champhekar, Ruixue Zhang, Salemiz Sandoval, Paige E. Krystofinski, Angel Garcia-Diaz, Giulia Parisi, Cristina Puig-Saus
Supplemental Figure 1: Hypothetical model of peripheral blood TCR-transgenic cell repopulation. Supplemental Figure 2: GLP team organizational chart. Supplemental Figure 3. Bone marrow transplant (BMT) optimization studies in HLA-A2/Kb transgenic mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a236dda1faa85487df2772f809b017e3
https://doi.org/10.1158/1078-0432.22468605.v1
https://doi.org/10.1158/1078-0432.22468605.v1